Abstract
Objective This study aimed to bridge the gap between the costliness and complexity of diagnosing Alzheimer’s disease by developing a scoring system with interpretable machine learning to predict the risk of Alzheimer’s using obtainable variables to promote accessibility and early detection.
Participants and Methods We analyzed 713 participants with normal cognition or mild cognitive impairment from the Alzheimer’s Disease Neuroimaging Initiative. We integrated cognitive test scores from various domains, informant-reported daily functioning, APOE genotype, and demographics to generate the scorecards using the FasterRisk algorithm.
Results Various combinations of 5 features were selected to generate ten scorecards with a test area under the curve ranging from 0.867 to 0.893. The best performance scorecard generated the following point assignments: age < 76 (-2 points); no APOE ε4 alleles (-3 points); Rey Auditory Verbal Learning Test <= 36 items (4 points); Logical Memory delayed recall <= 3 items (5 points); and Functional Assessment Questionnaire <= 2 (-5 points). The probable Alzheimer’s development risk was 4.3% for a score of -10, 31.5% for a score of -3, 50% for a score of -1, 76.3% for a score of 1, and greater than 95% for a score of > 6.
Conclusions Our findings highlight the potential of these interpretable scorecards to predict the likelihood of developing Alzheimer’s disease using obtainable information, allowing for applicability across diverse healthcare environments. While our initial scope centers on Alzheimer’s disease, the foundation we have established paves the way for similar methodologies to be applied to other types of dementia.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The authors have no funding to report.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used ONLY openly available human data that were originally located at https://adni.loni.usc.edu/)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵1 Data used in preparation of this article were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report.
Data Availability
Data used in the analysis were obtained from 722 the Alzheimer’s Disease Neuroimaging Initiative 723 (ADNI) database (https://adni.loni.usc.edu/)
